People

Andrea Sorrentino

Associate

Sorrentino, Andrea

Andrea Sorrentino's practice focuses on all aspects of corporate law. She represents public and private companies in a variety of industries, including technology, life sciences and financial services.

Ms. Sorrentino was a summer associate at WilmerHale in 2014. Prior to joining the firm, she was a legal intern in the Public Integrity Division of the Massachusetts Attorney General's Office, where she researched and drafted memoranda on procedural and substantive matters, including selective prosecution, professional responsibility and campaign finance issues. She also analyzed public corruption cases to identify factors that contributed to successful dispositions.

Previously, Ms. Sorrentino was a paralegal and a legal intern at two boutique law firms in New York, and an intern with the Free Legal Advice Centre in Dublin, Ireland.

Publications & News

View

January 19, 2018

WilmerHale Represents Pandion Therapeutics in $58M Series A Financing

On January 18, 2018, Pandion Therapeutics, Inc., a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, announced its $58 million Series A financing.

January 3, 2018

WilmerHale Represents Viamet Pharmaceuticals in Acquisition by NovaQuest Capital Management

Viamet Pharmaceuticals (NC), Inc. today announced that it has entered into an agreement with NovaQuest Capital Management, L.L.C. for the acquisition of Viamet Pharmaceuticals, including the company's product candidate, VT-1161.

April 28, 2017

2017 Venture Capital Report

The 2017 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as a look at the following issues: steps startups should take now if they plan to secure a Series A round in 2017; common structures for management carve-out plans; best practices for private companies setting option exercise prices; the benefits of investing in qualified small business stock; and trends in venture capital financing terms, convertible debt terms and VC-backed company M&A deal terms.

December 28, 2016

WilmerHale Counsels Tokai Pharmaceuticals in Share Purchase Agreement with Otic Pharma

The WilmerHale deal team included Partners Hal Leibowitz, Stuart Falber, Belinda Juran, Bill Caporizzo and Amy Null; Counsel Michael Welhouse; Senior Associate Ryan Mitteness; and Associate Andrea Sorrentino.

August 10, 2016

WilmerHale Advises Orbitera in Acquisition by Google

The Google Cloud Platform team shares Orbitera's vision for seamless purchase and deployment of IT services across heterogeneous cloud infrastructure.

July 28, 2016

WilmerHale Advises Argos Therapeutics in Pricing of $50M Public Offering

Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, announced the pricing of its public offering of $50 million.

May 3, 2016

WilmerHale Represents MKS Instruments in Acquiring Newport Corporation and Securing $980 Million Acquisition Financing

WilmerHale represented its long-time client MKS Instruments, Inc., a global technology provider, in closing its acquisition of Newport Corporation, a worldwide leader in photonics solutions, for approximately $905 million.

March 24, 2016

2016 M&A Report

Our 2016 M&A Report offers a detailed review of, and outlook for, the global M&A market. Other highlights include a comparison of deal terms in public and private acquisitions; updates on takeover defenses and public company deal litigation; practical guidance on avoiding antitrust violations in pre-merger integration planning; a look at what buyers need to know about appraisal claims in private company mergers; and a survey of key terms and issues in sales of VC-backed companies.

February 23, 2016

WilmerHale Advises MKS Instruments on $980 Million Acquisition of Newport Corporation

WilmerHale is advising its long-time client MKS Instruments, Inc. on its acquisition of Newport Corporation in an all-cash transaction valued at approximately $980 million.

Practices

Skip Navigation Links.

Education

JD, magna cum laude, Boston University School of Law, 2015, Editor, Boston University Law Review, Edward F. Hennessey Distinguished Scholar

BA, Political Science, summa cum laude, Boston University, 2011

Bar Admissions

Massachusetts

Skip Navigation Links.